The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
Abstract
Background and Aims: Antibodies to infliximab reduce serum infliximab with loss of clinical benefit, but undetectable trough serum concentrations of infliximab may occur without antibody formation. The relationship between trough serum infliximab and clinical outcomes was evaluated in acute ulcerative colitis. Methods: In a cohort of 115 patients with ulcerative colitis treated with three-dose induction followed by scheduled maintenance infliximab, rates of clinical remission, colectomy, antibodies to infliximab and trough serum infliximab were determined. Results: Rates of remission were 32% at week 10 and 37% at week 54. Colectomy occurred in 40% of patients, at a median of 5.3 (IQR 1.9–12.1) months. Detectable trough serum infliximab was present in 39% of patients and, among patients with undetectable infliximab, 41% were antibody positive and 20% were antibody negative. For antibody-positive and antibody-negative patients, rates of remission (18% vs 14%), endoscopic improvement (25% vs 35%) and colectomy (52% vs 59%) were not different. A detectable serum infliximab was associated with higher rates of remission (69% vs 15%; p<0.001) and endoscopic improvement (76% vs 28%, p<0.001). An undetectable serum infliximab predicted an increased risk for colectomy (55% vs 7%, OR 9.3; 95% CI 2.9 to 29.9; p<0.001). Concurrent immunosuppression was not associated with clinical outcomes. Conclusions: For patients with ulcerative colitis treated with infliximab, a detectable trough serum infliximab predicts clinical remission, endoscopic improvement and a lower risk for colectomy. An undetectable trough serum infliximab, irrespective of antibody status, is associated with less favourable outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Järnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Hanauer, S. B., Wagner, C. L., BALA, M. M., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 636
Maser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
Self-citationVermeire, S., Noman, M., Van Assche, G., Baert, F., D’Haens, G., & Rutgeerts, P. (2007) · Gut · doi:10.1136/gut.2006.099978 · Cited by 602
St.Clair, E. W., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T., Kavanaugh, A., & Keystone, E. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10302 · Cited by 417
Probert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Henriksen, M., Jahnsen, J., Lygren, I., Sauar, J., Kjellevold, Y., Schulz, T., Vatn, M. H., & Moum, B. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000225339.91484.fc · Cited by 268
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
Lawson, M. M., Thomas, A. G., & Akobeng, A. K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005112.pub2 · Cited by 229
Arts, J., D’Haens, G., Zeegers, M., Van Assche, G., Hiele, M., D’Hoore, A., Penninckx, F., Vermeire, S., & Rutgeerts, P. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200403000-00002 · Cited by 227
Predictors of early response to infliximab in patients with ulcerative colitis
Ferrante, M., Vermeire, S., Katsanos, K. H., Noman, M., Van Assche, G., Schnitzler, F., Arijs, I., De Hertogh, G., Hoffman, I., Geboes, K., et al. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20054 · Cited by 192
Systematic review: infliximab therapy in ulcerative colitis
Gisbert, J. P., González‐Lama, Y., & MATÉ, J. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03131.x · Cited by 135
Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis
Xu, Z., Seitz, K., Fasanmade, A. A., Ford, J. A., Williamson, P., Xu, W., Davis, H. M., & Zhou, H. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008316886 · Cited by 109
Gustavsson, A., Halfvarson, J., Magnuson, A., Sandberg–Gertzén, H., Tysk, C., & Järnerot, G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01435.x · Cited by 68
Dünker, N., Schmitt, K., Schuster, N., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.32991 · Cited by 55
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Danese, S., & Fiocchi, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1102942 · Cited by 1,102
Metadata
- Authors
- Seow, C. H., Newman, A., Irwin, S. P., Steinhart, A. H., Silverberg, M. S., & Greenberg, G. R.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2009-08-02
- Volume
- 59
- Issue
- 01
- Pages
- 49-54
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2146963207
- Cited by
- 536
- References
- 21
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.